Physician profile
Nevin Arora
NPI 1518191949
$5,203.43
in general payments reported to CMS, 2019-2025
8 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what a typical Sleep Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $152 · 2021: $2,210 · 2022: $402 · 2023: $388 · 2024: $504 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,558 · Education: $290 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,558.49 |
| Education | $289.97 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $3,496.59 | 2019-2025 | |
| Harmony Biosciences LLC | $583.43 | 2020-2025 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $438.65 | 2024-2025 | Lumryz |
| Inspire Medical Systems, INC. | $348.57 | 2023-2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $154.16 | 2022-2023 | Quviviq |
| Axsome Therapeutics, INC. | $117.37 | 2025 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $47.45 | 2025 | |
| 3b Medical, INC. | $17.21 | 2025 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nevin Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.